NanoString Technologies (NSTG) is a biotechnology company at the forefront of developing cancer diagnostic tools.
In fact, the company uses genomic data to detect cancer early at a molecular level, as well as better target residual areas of the disease. This means NSTG effectively uses DNA to find and treat cancer before it becomes a major issue.
And while it’s a relatively new publicly-traded company, NSTG is making progress in achieving profitability.
In its most recent quarter, NSTG reported an earnings loss per share of $0.60, largely in-line with Wall Street’s expected loss per share of $0.59. The company’s EBITDA was a loss of $17.3 million versus the expected decline of $21.5 million.
Meanwhile, revenue came in ahead of the $32.3 million estimate at $33.9 million.
Currently, NSTG is partnered with Parker Institute on a molecular characterization project for cellular therapies.
Through the collaboration, the companies will develop standardized approaches to cell therapy regimens that could help improve patient outcomes across a variety of cancer types.
And as the biotech company continues to research breakthrough therapies, it could be at the forefront of a new era of cancer treatments.
The Alzheimer's Association estimates that, “caring for individuals with Alzheimer's will cost American society $20 trillion.”
Jim Cramer says a drug that could treat the disease “would be the biggest drug ever.”
The Wall Street Journal says the “financial benefits would be massive.”
One small biotech holds the key to a revolution in treating this dreaded disease.
Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.